Dark Streaming/Mobile Old Site Home Products Help Contact Us Your Account System Status
Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS
14:50:21 EDT Fri 19 Apr 2024
Enter Symbol
or Name
USA
CA



Q:SNDX - SYNDAX PHARMACEUTICALS INC - http://www.sandstormresources.com
Sym-XBid - AskLastChg%ChVol$Vol#TrOpen-Hi-LoYear Hi-LoLast TrNewsDelay
SNDX - Q0.320.49·20.510.420.50+0.010.0333.46,6763,99020.42  21.12  20.4225.34  11.21514:33:01Apr 1015 min RT 2¢

Recent Trades - Last 10 of 3990
Time ETExPriceChangeVolume
14:33:01Q20.500.0136
14:32:50Q20.500.01100
14:32:34Q20.500.0111
14:32:34Q20.500.0111
14:32:31Q20.500.0121
14:32:31Q20.500.0115
14:32:31Q20.500.0115
14:32:31Q20.500.0114
14:32:31Q20.500.0111
14:32:30Q20.500.019

Sign-up for a FREE 30-day Stockwatch subscription and SEE NO ADS

Recent Bulletins
Date ETSymbolTypeHeadline
2024-04-10 16:05U:SNDXNews ReleaseSyndax Announces Participation at the Stifel 2024 Virtual Targeted Oncology Forum
2024-04-08 07:00U:SNDXNews ReleaseSyndax Presents Positive Pediatric Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at ASPHO Plenary Session
2024-04-05 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-03-28 07:00U:SNDXNews ReleaseSyndax Announces Completion of Enrollment in AUGMENT-101 Pivotal Trial Cohort of Patients with Relapsed/Refractory mNPM1 Acute Myeloid Leukemia
2024-03-26 16:05U:SNDXNews ReleaseSyndax Announces FDA Priority Review of NDA for Revumenib for the Treatment of Relapsed/Refractory KMT2Ar Acute Leukemia
2024-03-18 07:00U:SNDXNews ReleaseSyndax Announces Appointment of Steven Closter as Chief Commercial Officer
2024-03-01 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-27 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Clinical and Business Update
2024-02-26 07:00U:SNDXNews ReleaseSyndax Announces Participation at Two Upcoming Investor Conferences
2024-02-20 16:05U:SNDXNews ReleaseSyndax to Announce Fourth Quarter and Year-end 2023 Financial Results and Host Conference Call and Webcast on February 27, 2024
2024-02-02 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-02-01 16:10U:SNDXNews ReleaseSyndax Announces Participation at Two Upcoming Investor Conferences
2024-01-05 16:05U:SNDXNews ReleaseSyndax Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
2024-01-02 16:05U:SNDXNews ReleaseSyndax Announces Presentation at 42nd Annual J.P. Morgan Healthcare Conference
2024-01-02 07:00U:SNDXNews ReleaseSyndax Highlights Recent Updates and Anticipated 2024 Milestones
2023-12-19 16:16U:SNDXNews ReleaseSyndax Announces Closing of Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
2023-12-14 23:07U:SNDXNews ReleaseSyndax Announces Pricing of $200 Million Public Offering of Common Stock
2023-12-14 16:00U:SNDXNews ReleaseSyndax Announces Proposed $150 Million Public Offering of Common Stock
2023-12-12 12:00U:SNDXNews ReleaseSyndax Presents Positive Data from Pivotal AUGMENT-101 Trial of Revumenib in Relapsed/Refractory KMT2Ar Acute Leukemia at Late-Breaking Oral Presentation During 65th ASH Annual Meeting
2023-12-11 07:30U:SNDXNews ReleaseSyndax Announces Positive Data for Revumenib in Patients with Acute Leukemias from the BEAT AML, SAVE AML and AUGMENT-102 Phase 1 Combination Trials